Oxidised Apolipoprotein Peptidome Characterises Metabolic Dysfunction‐Associated Steatotic Liver Disease
Liver International · 2025-02 · 45 (2)
DOI: 10.1111/liv.16200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 17.01.2025. Verfasst von Gabriele Mocciaro und 11 weiteren Autor:innen. Beteiligte Einrichtung: Roger Williams Institute of Liver Studies, Foundation for Liver Research, London, UK. Hauptthemen laut MEDLINE: Apolipoprotein C-III, Fatty Liver, Apolipoproteins E, Apolipoproteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, This research was supported by NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) funding to V.A., M.A., and M.V.The initial establishment of the cohor….
Abstract (Originalsprache)
Background
Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) encompasses a spectrum of histological conditions ranging from simple steatosis to fibrosing steatohepatitis, and is a risk factor for cardiovascular diseases (CVD). While oxidised apolipoproteins A and B have been linked to obesity and CVD, the association between other oxidised apolipoproteins and MASLD is yet to be established. To fill this gap, we characterised the circulating serum peptidome of patients with MASLD.
Methods
We studied the serum of 87 biopsy‐confirmed MASLD patients and 20 age‐ and sex‐matched control (CTRL) subjects. We first employed an untargeted LC‐MS/MS peptidomics approach (9 CTRL, 32 MASLD) to identify key hits differentially modulated, and subsequently validated the most relevant findings through targeted peptidomics in an enlarged study population (87 MASLD and 20 CTRL).
Results
Untargeted serum peptidomics identified several oxidised apolipoprotein peptide fragments, including ApoE and ApoC‐III, significantly upregulated in MASLD compared to CTRL. Specifically focusing on the oxidative status of intact ApoC‐III, studied through its major glycoforms (ApoC‐III 0 , ApoC‐III i and ApoC‐III ii ), we observed a marked reduction in non‐oxidised forms of these circulating peptides alongside substantially increased levels of their oxidised proteoforms in MASLD versus controls (but not within the disease stages). Oxidised ApoE and ApoC‐III peptide fragments were also significantly correlated with obesity, insulin resistance, dyslipidaemia and transaminases, suggesting a potential link between circulating apolipoprotein oxidation and systemic/hepatic metabolic dysfunction.
Conclusion
Our data reveals a previously unreported oxidised apolipoprotein profile associated with MASLD. The functional and clinical implications of these findings warrant further mechanistic investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Roger Williams Institute of Liver Studies, Foundation for Liver Research, London, UK.
- Institute of Metabolic Science Metabolic Research Laboratories, Addenbrooke's Hospital, Cambridge, UK.
- Liver Unit, Cambridge NIHR Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
- Faculty of Health and Life Sciences, Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.
- The Rowett Institute, Foresterhill Campus, University of Aberdeen, Aberdeen, UK.
- University of Bari "Aldo Moro", Department of Interdisciplinary Medicine, Clinica Medica "C. Frugoni", Bari, Italy.
ORCID-Profile: Gabriele Mocciaro, Amy L George, Michele Vacca
Förderung
- Wellcome Trust
- Medical Research Council
- This research was supported by NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) funding to V.A., M.A., and M.V.The initial establishment of the cohor…
- British Heart Foundation
Zitieren
APA
Mocciaro, G., George, A. L., Allison, M., Frontini, M., Huang-Doran, I., Reiman, F., Gribble, F., Griffin, J. L., Vidal-Puig, A., Azzu, V., Kay, R., & Vacca, M. (2025). Oxidised Apolipoprotein Peptidome Characterises Metabolic Dysfunction‐Associated Steatotic Liver Disease. Liver International, 45(2). https://doi.org/10.1111/liv.16200
Vancouver
Mocciaro G, George AL, Allison M, Frontini M, Huang-Doran I, Reiman F, et al. Oxidised Apolipoprotein Peptidome Characterises Metabolic Dysfunction‐Associated Steatotic Liver Disease. Liver International. 2025;45(2). doi:10.1111/liv.16200
BibTeX
@article{Mocciaro2025,
author = {Mocciaro, Gabriele and George, Amy L and Allison, Michael and Frontini, Mattia and Huang-Doran, Isabel and Reiman, Frank and Gribble, Fiona and Griffin, Julian L and Vidal-Puig, Antonio and Azzu, Vian and Kay, Richard and Vacca, Michele},
title = {Oxidised Apolipoprotein Peptidome Characterises Metabolic Dysfunction‐Associated Steatotic Liver Disease},
journal = {Liver International},
year = {2025},
volume = {45},
number = {2},
doi = {10.1111/liv.16200}
}
EUVIMED